{"i": ["vascular endothelial growth factor ( VEGF ) targeting antibody bevacizumab with cisplatin plus fluoropyrimidine vs placebo plus chemotherapy", "ramucirumab", "bevacizumab", "becacizumab", "capecitabine", "capecitabine .", "bevacizumab -", "placebo", "antiangiogenic therapy", "cisplatin", "chemotherapy", "fluorouracil", "anti - VEGF", "bevacizumab .", "trebananib"], "o": ["Median baseline plasma Ang - 2 levels", "plasma or serum Ang - 2", "Baseline plasma Ang - 2 levels", "median OS", "low Ang - 2 levels", "baseline plasma Ang - 2 levels", "survival rates", "circulating Ang - 2 levels", "Ang - 2 plasma levels", "baseline Ang - 2 levels", "incidence and mortality", "plasma Ang - 2", "baseline Ang - 2 and PFS", "PFS", "VEGF levels", "OS or PFS", "Ang - 2 levels .", "overall response rate", "liver metastasis", "PFS or OS .", "Low Ang - 2 levels", "HR for PFS", "baseline plasma Ang - 2", "Plasma", "progression - free survival ( PFS )", "plasma Ang - 2 levels", "frequency of diffuse gastric cancer", "VEGF - A levels", "Ang - 2 protein levels", "overall survival ( OS )", "frequency of patients with \u2a7e 2 metastatic sites", "Median OS", "Ang - 2 baseline levels", "PFS and OS", "median Ang - 2 levels", "Ang - 2 production .", "new metastatic lesions in the liver", "frequency of liver metastasis ( LM )", "survival benefit", "later line chemotherapy exposure", "pretherapeutic Ang - 2 levels", "Ang - 2", "VEGF", "bone metastasis", "frequency of bone lesions", "Ang - 2 expression", "HR for OS", "occurrence of liver metastasis", "frequency of liver metastasis", "Plasma Ang - 2 levels", "OS", "odds ratio", "median biomarker value", "Ang - 2 levels"]}